esses grew and remained profitable, on a continued surge in sales. We
have successfully implemented our medical diagnostics and medical
disposable products distribution plans and these businesses have generated
almost six million dollars in sales during the first half of fiscal 2008,
quite an accomplishment even in a slowing national economy. We are
currently maintaining momentum in what is usually our slowest quarter,
perhaps signifying further developments later this year."
For the first six months of fiscal 2008, InstaCare reported revenues of
$5,818,076, a gain of 174% from $2,120,131 recorded during the first six
months of fiscal 2007. The Company reported an operating profit of $287,034
during the first six months of fiscal 2008 compared with an operating loss
of $430,140 recorded during the first six months of fiscal 2007. The
Company reported net income of $59,381 for the first six months of fiscal
2008, compared with a net loss of $553,756 reported for the first six
months of fiscal 2007.
This release contains forward-looking statements about our business or
financial condition that reflect our assumptions and beliefs based on
information currently available. We can give no assurance that the
expectations indicated by such forward-looking statements will be realized.
There may be other risks and circumstances that we are unable to predict.
When used in this release, words such as "believes," "expects,"
"forecasts," "intends," "projects," "plans," "anticipates," "estimates" and
similar expressions are intended to identify forward-looking statements,
although there may be certain statements not accompanied by such
For further information, visit the company's Web Site:
info@inPage: 1 2 3 4 5 6 Related biology technology :1
. BioSpecifics Technologies Corp. Reports Second Quarter 2008 Financial Results2
. Vista Partners Updates Coverage on Raptor Pharmaceuticals Corp. (OTC Bulletin Board: RPTP)3
. Norgen Biotek Corp. Launches Four New Kits for the Purification of RNA and DNA from Plants and Fungi4
. Access Pharmaceuticals Signs Merger Agreement to Acquire MacroChem Corp.5
. Daniel B. Dubin, M.D., Joins NanoBio Corp.s Board of Directors6
. Raptor Pharmaceuticals Corp. Announces Presentation at 5th International Cystinosis Conference 20087
. Raptor Pharmaceuticals Corp. To Present at BIO 2008 International Convention8
. BioSpecifics Technologies Corp. Announces Additional Sales of Stock in Private Placement Offering9
. Raptor Pharmaceuticals Corp. Receives FDA Orphan Drug Designation for Cysteamine in Huntingtons Disease10
. BioSpecifics Technologies Corp. Announces Sale of Stock in Private Placement Offering11
. CellCyte Genetics Corp. Appoints Jay H. Traverse to Scientific Advisory Board as Clinical Consultant